Estradiol MHT Alzheimer Biomarkers Postmenopausal Women
Summary of the Research on Menopausal Hormone Therapy (MHT) and Alzheimer’s Biomarkers
This research investigated the impact of menopausal hormone therapy (MHT) – specifically 1mg daily oral 17-β estradiol, with or without vaginal progesterone – on biomarkers associated with Alzheimer’s disease in postmenopausal women. Here’s a breakdown of the key findings:
Study Design:
* Participants: 438 postmenopausal women.
* Method: Randomized controlled trial comparing MHT to placebo.
* Biomarkers Measured: Aβ40,Aβ42,Aβ42/Aβ40 ratio,GFAP,nfl,and ptau181 (measured in blood plasma over 2.5 years).
* Analysis: Researchers looked at how MHT affected the rate of change in these biomarkers, considering the timing of menopause (early vs. late) and ApoE4 gene status (a genetic risk factor for Alzheimer’s).
Key Findings:
* Overall: MHT significantly accelerated the decline in Aβ40 levels compared to placebo (p = .049). However, effects on other biomarkers were not statistically significant overall.
* Early Postmenopause:
* There was a trend towards greater declines in Aβ42 and increases in the Aβ42/Aβ40 ratio with MHT, but these differences weren’t statistically significant.
* GFAP levels declined in both groups, with a slightly greater decline in the MHT group.
* ApoE4 Carriers (in early postmenopause): MHT was associated with a more pronounced decline in both Aβ40 and Aβ42 compared to placebo, but again, this wasn’t statistically significant.
* Late Postmenopause: MHT showed no significant effects on any of the biomarkers measured.
Implications:
The study suggests that MHT containing estradiol may have negative impacts on certain Alzheimer’s biomarkers, particularly Aβ40. However, the findings are not conclusive, and effects seem to be most pronounced in women in early postmenopause, and possibly more concerning for those who carry the ApoE4 gene.
Important note: The article emphasizes the importance of postmenopausal women discussing their health and potential risks/benefits of MHT with their healthcare professionals and pharmacists.